Ritonavir-PEG 8000 Amorphous Solid Dispersions: In Vitro and in Vivo Evaluations

Journal of Pharmaceutical Sciences

Volumn 93, Issue 3, 2004, Pages 563-570

  Law, Devalina ^a   Schmitt, Eric A ^a   Marsh, Kennan C ^a   Everitt, Elizabeth A ^a   Wang, Weili ^a   Fort, James J ^b   Krill, Steven L ^c   Qiu, Yihong ^a  

^a ABBOTT LABORATORIES   (United States)

^b Research and Development Center   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Amorphous; Bioavailability; Cell lines; In vivo in vitro correlation (IVIVC); Inhibition; Ritonavir; Solid dispersion

Indexed keywords

MACROGOL 8000; RITONAVIR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTAL; DISPERSION; DISSOLUTION; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DETERMINATION; DRUG FORMULATION; DRUG PENETRATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; SOLID;

EID: 1542410398     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10566     Document Type: Article

References (26)

1. Breitenbach J. 2002. Melt extrusion: From process to drug delivery technology. Eur J Pharm Biopharm 54:107-117.
2. Law D, Schmitt EA, Qiu Y, Wang W, Fort JJ, Krill S. 1999. Amorphous and eutectic solid dispersion systems of model lipophilic compound, fenofibrate. AAPS Pharm Sci 1:S-525.
3. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
4. Lacoulonche F, Chauvet A, Masse J, Egea MA, Gracia ML. 1998. An investigation of FB interactions with poly(ethylene) glycol 6000, poly(ethylene) glycol 4000 and poly-ε-caprolactone by thermoanalytical and spectroscopic methods and modeling. J Pharm Sci 87:543-551.
5. Zerrouk N, Chemtob C, Arnaud P, Toscani S, Dugue J. 2002. In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. Int J Pharm 225:49-62.
6. Ford JL, Rubinstein MH. 1978. Phase equlibria and dissolution rates of indomethacin-polyethylene glycol 6000 solid dispersions. Pharm Acta Helv 53: 93-98.
7. Law D, Wang W, Schmitt EA, Long MA. 2002. Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation. Pharm Res 19:315-321.
8. Law D, Krill SL, Schmitt EA, Fort JJ, Qiu Y, Wang W, Porter WR. 2001. Physicochemical considerations n the preparation of amorphous ritonavir/PEG 8000 solid dispersions. J Pharm Sci 90(8): 1015-1025.
9. Marsh KC, Eiden E, McDonald E. 1997. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatography B 704:307-313.
10. Semonelli AP, Mehta SC, Higuchi WI. 1969. Dissolution rate of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. J Pharm Sci 58:538-549.
11. Hilgers AR, Conradi RA, Burton PS. 1990. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 7:902-910.
12. Yee S. 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 14: 763-766.
13. Zou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. 2002. Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci 91:1863-1872.
14. Aungst BJ, Nguyen NH, Bulgarelli JP, Oates-Lenz K. 2000 The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm Res 17:1175-1180.
15. Mah SM, Rubas W. 1996. Vinblastine, a substrate for P-glycoprotein, flux across Caco-2 monolayers and rabbit jejunum. In: Proceedings of the 23rd International Symposium on Controlled Release of Bioactive Materials, pp 255-256.
16. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TR. 1998. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glyco-protein (P-gp) in human cultured cells. J Acquired Immune Deficiency Syndrome Human Retrovirol 19(3):203-209.
17. van der Spandt ICJ, van Fessem JMK, Voorwinden LH, Gaillard PJ, de Boer AG, Breimer DD. 2000. Anti-microtubule drugs have disruptives effects on the in vitro blood-brain barrier after inhibition of P-glycoprotein and can be used to characterize P-glycoprotein modulators and substrates. Fundam Clin Pharmacol 14(1):57.
18. Dupuis ML, Tombesi M, Cianfriglia M. 2002. Modulation of the multidrug resistance (MDR) phenotype in CEM MDR cells simultaneously exposed to anti HIV-1 protease inhibitor (PI's) and cytotoxic drugs. Annali Dell'Instituto Superiore di Sanita 38(4):387-392.
19. FDA Guidance for Industry "Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Dosage Forms Based on a Biopharmaceutics Classification System"; 8/2000.
20. Gutmann H, Fricker GT, Michael MS, Beglinger C, Drewe J. 1999. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm Res 16:402-407.
21. Crowe A, Lemaire M. 1998. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin. Pharm Res 15:1666-1672.
22. Nerurkar MM, Burton PS, Borchardt RT. 1996. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 13: 528-534.
23. Dressman JB, Yamada K. 1991. Animal models for oral drug absorption, in pharmaceutical bioequivalence. New York: Marcel Dekker, pp 235-266.
24. Kahlson G, Rosengren E, Svahn D, Thunberg R. 1964. Mobilization and formation of histamine in the gastric mucosa as related to acid secretion. J Physiol 174:400-416.
25. Akimoto M, Nagahata N, Furuya A, Fukushima K, Higuchi S, Suwa T. 2000. Comparison of canine and human gastrointestinal physiology. Eur J Pharm Biopharm 49:99-102.
26. FDA Guidance for Industry "Extended Release Oral Solid Dosage Forms: Development, Evaluation and Application of In vitro/In vivo Correlations"; 9/1997.